← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Biomimetix Jv, Llc
Englewood, CO
$10,476,802
Total funding
4
Grants
Funding over time
peak $3.2M · FY2015–22$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$10,476,802 · 4
By mechanism
R44$8,301,627 · 2
N43$1,700,000 · 1
R41$475,175 · 1
Investigators at Biomimetix Jv, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas$2,000,000
R44 · FY2021 · CA
BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas$2,000,000
R44 · FY2020 · CA
IGF::OT::IGF RADIOPROTECTOR FOR HEAD AND NECK CANCERPERIOD OF PERFORMANCE: 05/09/2016 - 05/08/2018$1,500,000
N43 · FY2016 · CA
BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas$1,023,555
R44 · FY2016 · CA
BMX-001 as a Therapeutic Agent for Treatment of Multiple Brain Metastases.$1,000,000
R44 · FY2020 · CA
BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas$976,447
R44 · FY2015 · CA
BMX-001 as a Therapeutic Agent for Treatment of Multiple Brain Metastases.$600,000
R44 · FY2022 · CA
BMX-001 as a Therapeutic Agent for Treatment of Multiple Brain Metastases.$400,000
R44 · FY2021 · CA
BMX-001 as a Therapeutic Agent for Treatment of Multiple Brain Metastases.$300,000
R44 · FY2018 · CA
Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke.$247,352
R41 · FY2019 · NS
Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke.$227,823
R41 · FY2020 · NS
IGF::OT::IGF RADIOPROTECTOR FOR HEAD AND NECK CANCER$200,000
N43 · FY2015 · CA
BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas$1,625
R44 · FY2022 · CA